NNBP Nanobac Pharmaceuticals Inc (CE)

Nanobac Pharmaceuticals Inc. (OTCBB:NNBP)�("Nanobac" or "the Company") announces that its proprietary CE marked Nano-Capture ELISA assay and Nano-Sero IgG ELISA assay currently manufactured by the Company�s subsidiary in Kuopio, Finland, will be made in the United States for use in clinical trials, FDA approval and expanded distribution. The Company�s diagnostics detect Calcifying Nano Particles (CNPs) which are linked to several diseases associated with pathologic calcification. The Company believes that its diagnostics will serve as biomarkers allowing for earlier identification, diagnosis, and treatment of such diseases. �The technology transfer of our proprietary diagnostic to a FDA approved U.S. manufacturing facility is a hallmark event for our company,� commented Dr. Benedict Maniscalco, Nanobac�s Co-Chair and Chief Medical Officer. �Bringing our manufacturing to the United States will potentially allow us to make our diagnostic a standard of care in U.S. Healthcare and represents a key step to transition from a research oriented company to one that rapidly develops products for sales and marketing worldwide.� For more information on the Company�s direction please refer to the Investor Section at www.nanobac.com. Further, for frequent updates on Nanobac�s progress please register as a friend of Nanobac at www.nanobac.com. Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com. Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.